AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05177640
Drug: 99mTc-Duramycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a single dose study of 99mTc-duramycin in healthy volunteers who will undergo serial SPECT scanning
Trial: NCT01013714
Drug: Routine Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-arrhythmic medications are continued for the duration of the study unless discontinued or adjusted to due to drug toxicity, intolerance, or ICD shock. All anti-arrhythmic medications (whether in the routine care or surgical arm) can be adjusted at the discretion of the treating physician.
Trial: NCT05994131
Drug: IN10018
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally taken once daily
Trial: NCT05682547
Drug: 0.1% hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% hyaluronate eye drops will be used to assess its usefulness in diabetic dry eye symptoms and compared to 3% Diquafosol tetrasodium eye drops.
Trial: NCT04646967
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See active comparator description
Trial: NCT04646967
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: See active comparator description
Trial: NCT04646967
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See experimental arm description
Trial: NCT03870334
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral once daily tablet
Trial: NCT04546633
Drug: KAF156
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provided as 50 mg or 100 mg tablets, to be taken QD 2 or 3 Days in combination with LUM-SDF, dose is based on body weight
Trial: NCT04546633
Drug: LUM-SDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provided as 60 mg, 120 mg or 240 mg powder in sachet, to be taken QD 2 or 3 Days in combination with KAF156, dose is based on body weight
Trial: NCT05528172
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ophthalmic solution
Trial: NCT02054559
Drug: R-CHOP
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (or prednisolone))
Trial: NCT05625724
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment for the control group
Trial: NCT05054803
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of 2 Intrathecal infusions of placebo at day 1 and at 3 months
Trial: NCT04218786
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The tablet will be given once daily for the span of the study
Trial: NCT06612593
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will receive 2 tablets twice daily
Trial: NCT06612593
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It includes Levodopa with a dose of 375 to 1000mg daily and Dopamine agonists with a dose of 1.5 to 5 mg daily.
Trial: NCT04722107
Drug: rAAV2/8-hCYP4V2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rAAV2/8-hCYP4V2 is developed by Chigenovo Co., Ltd., it contains recombinant adeno-associated virus serotype 8 (rAAV8) vectors which carry human CYP4V2 gene
Trial: NCT06458413
Drug: Utidelone Capsule Plus Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Utidelone Capsule: 60mg/m2/d, once daily, oral on an empty stomach, continuously administered for 1-5 days; Capecitabine tablets: 1000mg/m2, twice a day (daily dose 2000mg/m2), once in the morning and once in the evening, taken orally within 30 minutes after meals, and continuously administered for 14 days from day 1 to day 14.~Every 21 days is a cycle .
Trial: NCT04676061
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, tablet, orally, once daily for 7 consecutive days, every 4 weeks
Trial: NCT05486208
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC and/or IV.
Trial: NCT06336356
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally once daily.
Trial: NCT06715150
Drug: Azithromcyin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the placebo to be taken during the following days will be given to the patient.
Trial: NCT06729593
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In line with NIH treatment guidelines, corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.
Trial: NCT05978648
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2, intravenous drip, d1, Q3W, 4 cycles.
Trial: NCT04552899
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching PRM-151 will be administered by IV infusion on Days 1, 3 and 5, followed by infusions Q4W to Week 48.
Trial: NCT05667662
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules with 11.8 mg total powder (excipients only)
Trial: NCT06064058
Drug: Standard management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care with NSAIDs and acetaminophen for pain management
Trial: NCT05706987
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline
Trial: NCT05821387
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Product containing excipients with no active ingredients
Trial: NCT04682899
Drug: guideline-guided antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In guideline group, clinican make a decision of antibiotic precription based on the recommendations of GOLD guideline.
Trial: NCT04511897
Drug: An'ningpai
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An'ningpai Enteric Soft Capsules was a kind of expectorant, comprised with Eucalyptol, Limonene and Pinene. 300 mg, oral, three times daily for 12 months.
Trial: NCT04682743
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: received intravenous 0.9% normal saline over a 15-minute period.
Trial: NCT05262335
Drug: Anlotinib + Oxaliplatin + Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1. Before 6 cycles, Anlotinib 12mg, po.qd, d1-14; Capecitabine 850 mg/m2, po. bid, d1-14; Oxaliplatin 130 mg/m2, iv (D1). The above schemes are repeated every three weeks.~2. After 6 cycles, the regimen is changed to Anlotinib (12mg, po.qd, d1-14)+ Capecitabine (500 mg, po. bid, d1-21). The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity.
Trial: NCT03813095
Drug: APH-1501
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational drug product APH-1501 is CBD encapsulated in biodegradable polymer nanospheres, is a lyophilized powder intended for oral administration.
Trial: NCT05982106
Drug: TQ05105 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQ05105 tablet is a novel JAK2 inhibitor.
Trial: NCT05072028
Drug: [14C]DBPR108
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]DBPR108, single dose of 100 mg (radioactivity of 150 µCi), oral
Trial: NCT06194552
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo administered orally
Trial: NCT06574568
Drug: YKST02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCMA-CD3 bispecific antibody
Trial: NCT06415019
Drug: Naproxen (BAYH006689)
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BAYH006689 gel will be dispensed directly on the patch
Trial: NCT06415019
Drug: Placebo Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel will be dispensed directly on the patch
Trial: NCT06415019
Drug: A solution of 0.9% Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Saline will be dispensed directly on the patch.
Trial: NCT04987112
Drug: CAN1012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAN1012 IT injection (once every 4 weeks)
Trial: NCT04001010
Drug: PPP011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule inhaled 3 times a day with a vaporizer device
Trial: NCT04001010
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule inhaled 3 times a day with a vaporizer device
Trial: NCT04865029
Drug: Estradiol Cypionate 5 mg/ml
RxNorm normalized name: estradiol cypionate 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care along with Estradiol Cypionate 5mg intramuscular injection at admission.
Trial: NCT04710719
Drug: Triamcinolone Injection and 5-fluorouracil injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post surgical injection at site of keloid with TAC and 5FU for 3 injections
Trial: NCT05418465
Drug: Huangqi Guizhi Wuwu decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huangqi Guizhi Wuwu decoction, 100ml at a time, 2 times a day. Oral administration.
Trial: NCT06240481
Drug: Test Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: toothpaste \& mouthwash
Trial: NCT06240481
Drug: Control Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: toothpaste
Trial: NCT05901337
Drug: Convential medical treatment
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B participants received convential medical treatment for 8 weeks in the form of :~1. Vitamin D: The recommended dietary dose of vitamin D is 600 IU each day for adults 70 and younger .~2. Vitamine C: The recommended dietary dose 200 mg/day vitamin C~3. Anticoagulation drugs (blood thinners)Doctors usually prescribe low-molecular-weight heparin (enoxaparin) (30 mg), each given subcutaneously every 12 hours .
Trial: NCT04999761
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil will be administered with 800 mg/m2/day given by continuous intravenous infusion from Day 1 to Day 5.
Trial: NCT04999761
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil will be administered with 1000 mg/m2/day given by continuous intravenous infusion from Day 1 to Day 4.
Trial: NCT04891302
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo (5 capsules) once a day will be administered orally and can be taken regardless of food intake for 10 days
Trial: NCT06410300
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: checkpoint inhibitor per PI discretion
Trial: NCT05930613
Drug: Placebo (NaCl 0.9 % solution)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0,9% injected subcutaneously monthly from 5 weeks before embryo transfer until 7 weeks of gestation (injections at 5 and 1 week before embryo transfer, 3 and 7 weeks after embryo transfer) for a total of 4 injections in case of ongoing intrauterine pregnancy.
Trial: NCT05600686
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05600686
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00000998
Drug: Leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06455761
Drug: 68Ga-FAPI/18F-FDG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI or 3.7 MBq (0.1 mCi)/Kg 18F-FDG. Tracer doses of 68Ga-FAPI/18F-FDG will be used to detect tumors by PET/CT.
Trial: NCT01315691
Drug: Liposomal amikacin for inhalation
RxNorm normalized name: amikacin liposomal Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~* 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~* Administration time is approximately 13 minutes.~* Liposomal amikacin for inhalation will be administered for 28 days followed by 56 days off treatment.
Trial: NCT01315691
Drug: Placebo for liposomal amikacin for inhalation
RxNorm normalized name: amikacin liposomal Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.~* Administration procedures, volume and administration time are the same as for Arikace™.~* Placebo will be administered for 28 days.
Trial: NCT06145438
Drug: Levonogestrel + etinilestradiol (30 mcg, brand name Mycrogynon)
RxNorm normalized name: Etinilestradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug is administered orally at the same time every day
Trial: NCT05722262
Drug: K-877-ER
RxNorm normalized name: K+ 8 MEQ Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-877-ER tablet
Trial: NCT05722262
Drug: CSG452
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSG452 tablet
Trial: NCT05013216
Drug: Cohort A: Patients at high risk of developing pancreatic cancer.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. KRAS peptide vaccine with poly-ICLC adjuvant will be administered on Prime week 1, 3, and 5. Boost vaccinations with will be administered at week 13. All subjects will return to the study site approximately 28 days (+ 7 days) after the last vaccination for an End of Treatment (EOT) and safety evaluation.~2. Drug: up to 1.8 mg KRAS peptide vaccine + 0.5mg Poly-ICLC
Trial: NCT05013216
Drug: Cohort B: Patients must have evidence of a pancreatic cystic neoplasm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive KRAS peptide vaccine with poly-ICLC adjuvant as two prime vaccinations on weeks 1 and 2. Surgery is considered standard of care. Surgery will occur at the discretion of the treating hepatobiliary surgeon and is not dictated by this protocol. Subjects will return to the study site approximately at week 4 (+ 7 days) for a safety evaluation prior to surgery. Subjects will have an End of Treatment (EOT) visit at study Week 8 (+ 7 days).
Trial: NCT02451852
Drug: AZD9291
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9291 80mg tablet once daily, open label
Trial: NCT06307548
Drug: Aminolevulinic Acid
RxNorm normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06307548
Drug: Photodynamic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo PDT
Trial: NCT04864743
Drug: FRSW117
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a single dose.
Trial: NCT04927884
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose: 25 mg capsules taken twice per day by mouth (PO)~Frequency: to be taken Days 1-15 and 15-19 of each cycle (every 3 weeks)
Trial: NCT04858308
Drug: YYC506
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YYC506
Trial: NCT04858308
Drug: YYC506 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04858308
Drug: Control Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04553666
Drug: Epigallocatechin-3-Gallate (EGCG) plus Ascorbic Acid (Vitamin C)
RxNorm normalized name: Epigallocatechin-3-gallate
DrugBank: Epigallocatechin gallate (DB12116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800mg Epigallocatechin-3-Gallate (EGCG) plus 250mg Ascorbic Acid (Vitamin C) taken one time a day for twelve weeks
Trial: NCT06343116
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered weekly (dose of placebo depends on part A) until disease progression, unacceptable toxicity, withdrawal of consent or death due to any cause.
Trial: NCT06343116
Drug: Trifluridine/tipiracil
RxNorm normalized name: TRIFLURIDINE/TIPIRACIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifluridine/tipiracil will be administered (35 mg/m2) twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest.
Trial: NCT05469126
Drug: LY3502970
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05469126
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT06441318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered at protocol defined dose.
Trial: NCT06278948
Drug: Group CYS
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application short contact, of thin layer once daily at bedtime for 4 months
Trial: NCT05668897
Drug: placebo of GST-HG171
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study includes single-dose ascending and multiple-dose ascending studies. SAD study contains at least 4 dose groups of 150 mg, 300 mg, 600 mg and 900 mg. MAD study contains 1-3 dose groups which were evaluated in SAD study to be tolerated.
Trial: NCT06307223
Drug: supramolecular active zinc
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients received daily application of topical supramolecular active zinc anti-dandruff lotion for a duration of 8 weeks.
Trial: NCT05450913
Drug: Priformis intramuscular injection with %2 lidocain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Priformis intramuscular injection will be administered with 5 cc 2% lidocaine, accompanied by a nerve stimulator under ultrasound guidance
Trial: NCT04912843
Drug: NR082 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection（IVT）
Trial: NCT00990301
Drug: Moexipril HCl/ Hydrochlorothiazide 15mg/ 25mg Tablet, Paddock Laboratories, Inc.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: test drug
Trial: NCT00990301
Drug: Uniretic® 15mg/25mg Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: reference drug
Trial: NCT04449965
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This will be performed twice daily for two weeks.
Trial: NCT06122389
Drug: SHR2554; Chidamide analog tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR2554 + Chidamide analog tablets
Trial: NCT06122389
Drug: SHR2554 analog tablets; Chidamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR2554 analog tablets + Chidamide
Trial: NCT05728736
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be taken nightly for two consecutive nights
Trial: NCT00662077
Drug: Ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate endovenous 3 mg every 3 months
Trial: NCT05671627
Drug: DMARDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated as per clinician's judgement with any kind or combination of DMARDs with or without corticosteroids (corticosteroid regimens do not exceed 15 mg/day), following EULAR recommendations for RA treatment.
Trial: NCT05052853
Drug: Placebo Cap
RxNorm normalized name: PLACEBO CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of placebo as a comparator
Trial: NCT04777760
Drug: two and more doses of surfactant replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the preterm infants diagnosed with NRDS and/or NARDS will be administrated with two and more doses of surfactant
Trial: NCT06123702
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 placebo capsules
Trial: NCT05304845
Drug: DWP14012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium-competitive acid blocker
Trial: NCT05446961
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally capsules
Trial: NCT05908396
Drug: IGM-2644
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGM-2644 is an engineered, bispecific IgM antibody directed against CD3 and CD38. IGM-2644 is designed to bind to CD38 to selectively target and kill myeloma cancer cells through both T-cell dependent cellular toxicity (TDCC) and complement dependent cytotoxicity (CDC) activities.
Trial: NCT05893862
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT05947669
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone is available in tablets of 25 or 5 mg. Oral corticosteroids are internationally recommended as initial treatment for ir-colitis and ir-diarrhoea CTCAE grade 2 \[24-27\]. Participating sites will ensure availability of prednisolone for use in the study as part of the hospitals' standard supply.
Trial: NCT04627779
Drug: preemptive analgesia with flurbiprofen axetil
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: give flurbiprofen axetil 15 min before surgery